Since LECT2 was reported to antagonize MET receptor activation in hepatocellular carcinoma and non-small cell lung cancer (Chen et al., 2014; Hung et al., 2018), we speculated that LECT2 might regulate FOXM1 signaling by targeting MET. Here, MET is linked to hepatocellular carcinoma.